Insilico Medicine vs Isomorphic Labs IsoDDE

A side-by-side look at scores, pricing and features — with RECATOOLS' ASEAN-aware verdict for each.

Insilico Medicine AI that took a drug from concept to Phase III — now backed by Lilly. Visit Isomorphic Labs IsoDDE DeepMind's AI Drug Design Engine that doubles AlphaFold 3 accuracy in... Visit
RECATOOLS Score 8.7 / 10 8.2 / 10
Capability 9.5 9.5
Value for money 7 4
Ease of use 6.5 3.5
ASEAN readiness 7.5 3
API quality 7 2
Pricing Enterprise Enterprise
Free tier Chemistry42 cloud offers academic/startup access tiers; contact required None — no free or academic tier publicly available
Paid from Enterprise licensing; upfront deals from $10M milestone to $115M (Lilly) Enterprise partnership only; deals structured around R&D milestones (not per-seat or API)
Has API
Open source
Free to use
Users 13 of top 20 global pharma cos; 18.3% YoY subscription growth (2025) Not publicly disclosed; access limited to pharma partnership cohort
Founded 2014 2021
Maker Insilico Medicine (independent; HKEX: 3696) Alphabet Inc. (via Google DeepMind spinoff)
Verdict

Insilico Medicine holds a lead no other AI-native drug company currently matches: a molecule it designed from scratch has reached Phase III, with published peer-reviewed efficacy data behind it. The Pharma.AI stack — Pan...

Isomorphic Labs IsoDDE represents a genuine scientific leap in AI-driven drug design — its 50% accuracy on the hardest protein-ligand prediction benchmark, outperformance of physics-based gold standards in binding affini...

Full review → Full review →
← Back to AI Directory

Comparisons cover up to 4 tools. Scores are RECATOOLS editorial assessments; verify current pricing on each vendor's site.